Cabozantinib Significantly Prolongs PFS Over Sunitinib in Papillary RCC
February 14th 2021February 13, 2021 - Cabozantinib resulted in a statistically significant and clinically meaningful prolongation of progression-free survival compared with sunitinib in patients with metastatic papillary renal cell carcinoma.
Lenvatinib Plus Pembrolizumab Improves Survival, Responses Versus Sunitinib in Advanced RCC
February 13th 2021February 13, 2021 - Lenvatinib in combination with pembrolizumab resulted in improved overall survival, progression-free survival, and objective response rate over sunitinib in the frontline treatment of patients with advanced renal cell carcinoma.
Belzutifan/Cabozantinib Shows Promising Early Antitumor Activity in Advanced Clear Cell RCC
February 13, 2021 - Belzutifan used in combination with cabozantinib shrank tumors for 88% of patients and the disease control rate was 90% for patients with previously treated advanced clear cell renal cell carcinoma.
Molecular Signatures Linked With Long-Term Response to Apalutamide in Nonmetastatic CRPC
February 13th 2021February 13, 2021 - Certain molecular signatures at baseline were found to be independently linked with long-term response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.
BCG Plus N-803 Elicits Positive Responses, Tolerability in BCG-Unresponsive NMIBC CIS
February 13th 2021February 13, 2021 - Bacillus calmette-guérin plus N-803 demonstrated promising responses with a tolerable safety profile when used in patients with BCG-unresponsive, non–muscle-invasive bladder cancer carcinoma in situ
PSMA PET Imaging Agent 18F-DCFPyL Demonstrates High CLR and PPV
February 13th 2021February 13, 2021 - 18F-DCFPyL, an investigational prostate-specific membrane antigen PET imaging agent, was found to detect and localize metastatic lesions with a high correct localization rate and positive predictive value.
Enfortumab Vedotin Shows Superior Efficacy Over Chemo in Previously Treated Urothelial Carcinoma
February 13, 2021 - Enfortumab vedotin was found to have superior efficacy over chemotherapy when used in patients with advanced urothelial carcinoma who had received prior platinum-based chemotherapy and PD-1/L1 inhibition.
Enfortumab Vedotin Showcases Impressive Safety, Efficacy in Cisplatin-Ineligible Urothelial Cancer
February 13th 2021February 12, 2021 - Enfortumab vedotin elicited the highest response rates observed for any regimen examined in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.
Dr. Bergerot on Improved HRQoL With a Higher Starting Dose of Lenvatinib Plus Everolimus in RCC
February 13th 2021Cristiane Bergerot PhD, MS, BS, discusses how a higher starting dose of lenvatinib, to be combined with everolimus, can improve health-related quality of life in patients with renal cell carcinoma, as demonstrated in a phase 2 open-label trial.
Frontline Nivolumab/Cabozantinib Maintains Survival Benefit Over Sunitinib in Advanced RCC
February 12, 2021 - The combination of nivolumab and cabozantinib continued to showcase a superior survival benefit over single-agent sunitinib when used as first-line treatment in patients with advanced renal cell carcinoma.
Dr. Efstathiou on the rPFS Benefit Achieved With Apalutamide Regimen in mCRPC
February 12th 2021Eleni Efstathiou, MD, discusses the key findings of the placebo-controlled, double-blind phase 3 ACIS study of apalutamide and abiraterone acetate plus prednisone versus prednisone alone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.
Crossover Minimally Impacts OS Benefit Achieved With Darolutamide in ARAMIS Trial
February 12th 2021February 12, 2021 - Crossover from placebo to darolutamide appeared to have minimal impact on the overall survival benefit experienced by patients with nonmetastatic castration-resistant prostate cancer who were enrolled to the pivotal phase 3 ARAMIS trial.
Atezolizumab Demonstrates Clinical Activity in PD-L1–High Metastatic Urothelial Carcinoma
February 12th 2021February 12, 2021 - Atezolizumab monotherapy showed favorable outcomes compared with chemotherapy alone as frontline treatment for patients with cisplatin-ineligible IC2/3 advanced or metastatic urothelial carcinoma.
PSMA-Targeted Agent Shows Potential Utility in Identifying Relapsed Prostate Cancer
February 12th 2021February 12, 2021 - The novel prostate specific membrane antigen–targeted radiopharmaceutical for PET imaging technique, 18F-DCFPyL, demonstrated potential in identifying occult prostate cancer and more accurately characterizing disease burden.
Prolonged Treatment With Darolutamide Is Well Tolerated in Nonmetastic CRPC
February 12th 2021February 12, 2021 - The androgen receptor inhibitor darolutamide continues to show favorable tolerability in patients with nonmetastatic castration-resistant prostate cancer, even when given for a prolonged period of time.
Apalutamide Plus Abiraterone Reduces Risk of Progression in mCRPC
February 11th 2021February 11, 2021 - Adding apalutamide to abiraterone acetate and prednisone reduced the risk of radiographic progression or death by 30% in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy.
VERU-111 Elicits Early Efficacy Signals in Pretreated mCRPC
February 11th 2021February 11, 2021 - The novel tubulin inhibitor VERU-111 demonstrated early antitumor activity and a well-tolerated safety profile in patients with metastatic castration-resistant prostate cancer who failed a prior androgen receptor–targeting agent.